Literature DB >> 23041548

Carbon source and myc expression influence the antiproliferative actions of metformin.

Shiva Javeshghani1, Mahvash Zakikhani, Shane Austin, Miguel Bazile, Marie-José Blouin, Ivan Topisirovic, Julie St-Pierre, Michael N Pollak.   

Abstract

Epidemiologic and experimental data have led to increased interest in possible roles of biguanides in cancer prevention and/or treatment. Prior studies suggest that the primary action of metformin is inhibition of oxidative phosphorylation, resulting in reduced mitochondrial ATP production and activation of AMPK. In vitro, this may lead to AMPK-dependent growth inhibition if AMPK and its effector pathways are intact or to an energetic crisis if these are defective. We now show that the effect of exposure of several transformed cell lines to metformin varies with carbon source: in the presence of glutamine and absence of glucose, a 75% decrease in cellular ATP and an 80% decrease in cell number is typical; in contrast, when glucose is present, metformin exposure leads to increased glycolysis, with only a modest reduction in ATP level and cell number. Overexpression of myc was associated with sensitization to the antiproliferative effects of metformin, consistent with myc involvement in "glutamine addiction". Our results reveal previously unrecognized factors that influence metformin sensitivity and suggest that metformin-induced increase in glycolysis attenuates the antiproliferative effects of the compound.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041548     DOI: 10.1158/0008-5472.CAN-12-2907

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Potential applications for biguanides in oncology.

Authors:  Michael Pollak
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine.

Authors:  Ji Zhang; Natalya N Pavlova; Craig B Thompson
Journal:  EMBO J       Date:  2017-04-18       Impact factor: 11.598

3.  Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53.

Authors:  Hong-Tao Zhang; Yun-Long Wang; Jie Zhang; Qin-Xian Zhang
Journal:  Tumour Biol       Date:  2014-02

4.  Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.

Authors:  Sarah-Maria Fendt; Eric L Bell; Mark A Keibler; Shawn M Davidson; Gregory J Wirth; Brian Fiske; Jared R Mayers; Matthias Schwab; Gary Bellinger; Alfredo Csibi; Akash Patnaik; Marie Jose Blouin; Lewis C Cantley; Leonard Guarente; John Blenis; Michael N Pollak; Aria F Olumi; Matthew G Vander Heiden; Gregory Stephanopoulos
Journal:  Cancer Res       Date:  2013-05-17       Impact factor: 12.701

5.  Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.

Authors:  Laura Hulea; Simon-Pierre Gravel; Masahiro Morita; Marie Cargnello; Oro Uchenunu; Young Kyuen Im; Camille Lehuédé; Eric H Ma; Matthew Leibovitch; Shannon McLaughlan; Marie-José Blouin; Maxime Parisotto; Vasilios Papavasiliou; Cynthia Lavoie; Ola Larsson; Michael Ohh; Tiago Ferreira; Celia Greenwood; Gaëlle Bridon; Daina Avizonis; Gerardo Ferbeyre; Peter Siegel; Russell G Jones; William Muller; Josie Ursini-Siegel; Julie St-Pierre; Michael Pollak; Ivan Topisirovic
Journal:  Cell Metab       Date:  2018-09-20       Impact factor: 27.287

6.  Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.

Authors:  Elisabet Cuyàs; Salvador Fernández-Arroyo; Bruna Corominas-Faja; Esther Rodríguez-Gallego; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Rafael De Llorens; Jorge Joven; Javier A Menendez
Journal:  Oncotarget       Date:  2015-05-20

7.  Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

Authors:  Kıvanç Birsoy; Richard Possemato; Franziska K Lorbeer; Erol C Bayraktar; Prathapan Thiru; Burcu Yucel; Tim Wang; Walter W Chen; Clary B Clish; David M Sabatini
Journal:  Nature       Date:  2014-03-16       Impact factor: 49.962

8.  Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current.

Authors:  Marta Gritti; Roberto Würth; Marina Angelini; Federica Barbieri; Marta Peretti; Erika Pizzi; Alessandra Pattarozzi; Elisa Carra; Rodolfo Sirito; Antonio Daga; Paul M G Curmi; Michele Mazzanti; Tullio Florio
Journal:  Oncotarget       Date:  2014-11-30

9.  Metformin directly acts on mitochondria to alter cellular bioenergetics.

Authors:  Sylvia Andrzejewski; Simon-Pierre Gravel; Michael Pollak; Julie St-Pierre
Journal:  Cancer Metab       Date:  2014-08-28

10.  Metformin: a case of divide and conquer.

Authors:  Dimitrios Anastasiou
Journal:  Breast Cancer Res       Date:  2013-03-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.